Cell count alone is insufficient because it measures quantity, not the full quality or clinical suitability of a cell preparation. A number does not establish which cells are present, how many are alive, whether they function as intended, whether safety checks were passed, or whether the dose and route have evidence for your condition. A higher count is not, by itself, evidence of a safer or more effective treatment.
If two treatment quotes both say “100 million cells,” first check whether they mean total or viable cells, when the measurement was made, and whether the figure covers one administration or the entire course. The examples below are illustrations, not clinic quotes or recommended doses.

What a cell-count number actually measures
A cell count is a measurement of a defined population at a particular time. To interpret it, you need three details:
- What was counted. A total-cell count and a count of a selected cell population measure different things, even when taken from the same sample. Ask which method and cell population the report describes.
- When it was counted. A count before freezing is not the same as a count after thawing. Some cells do not survive freezing and thawing.
- What the number covers. The figure can mean one injection, one joint, one infusion bag, one visit, or a whole course. Without that unit, comparison falls apart.
The distinction between autologous and allogeneic sources matters too: autologous cells come from the patient; allogeneic cells come from a donor. Screening and monitoring requirements depend on the particular product and procedure. Neither source label establishes the quality of an individual batch.
Total count hides living cells
Viability is the proportion of cells classified as alive by the test used, at the time of measurement. A pre-freezing viability result does not establish the viable-cell count after thawing and preparation for administration. Viability also does not measure every aspect of cell function.
A quick bit of math makes the wording problem obvious. One preparation has 100 million total cells with 60 percent viability, so it holds about 60 million living cells. Another preparation has 80 million viable cells, so it holds about 80 million living cells. The first headline looks bigger. The second bag actually holds more living cells. That is just arithmetic. It is not a recommended dose or a clinic quote.
This calculation assumes the viability percentage applies to the same population as the total count. Even then, more viable cells do not automatically mean more benefit: identity, function, safety, and clinical evidence remain separate questions.
Count does not name the cells
A same-day tissue mixture, a culture-expanded population, and a purified or selected population can all carry the word cells on paper. What is actually inside them can be quite different, so the same count can describe very different material.
Identity testing asks which cells are present. For human multipotent mesenchymal stromal cells (MSCs), the 2006 International Society for Cellular Therapy position statement proposes three minimal laboratory criteria: adherence to plastic under standard culture conditions; a specified surface-marker pattern, including CD105, CD73, and CD90; and the ability to differentiate into bone, fat, and cartilage cell lineages in the laboratory.16923606 These are characterization criteria for that cell type, not a definition of every stem-cell product or proof that an injection repairs tissue in a patient.
Purity asks how much of the preparation is the intended cell population rather than other cells or unwanted material. A headline count cannot answer either question. Ask whether the reported number refers to viable cells of the intended type or a broader mixture.
Count shows presence, not function
Potency testing assesses biological activity relevant to the product’s intended effect. It addresses a different question from counting cells or measuring viability. Ask what activity the test measures and why it is relevant to the proposed use.
A laboratory activity result is not itself proof of benefit in patients. Clinical evidence must still support the particular product and use; a large cell count cannot substitute for that evidence.
Why a high count cannot prove safety
A count says nothing about sterility, infectious-disease screening, or manufacturing control. A batch with a big count can still fail basic safety checks.
Ask for the applicable donor-screening records, sterility results, processing controls, and criteria used to release the preparation for administration. Ask which results are available before treatment and how any pending or abnormal result is handled. These documents answer questions that the cell count cannot.
The FDA’s consumer information lists safety concerns with illegally marketed, unapproved regenerative products: blindness, tumor formation, neurological events, bacterial infections including life-threatening blood infections, collection- and administration-site reactions, unwanted inflammatory or immune responses, cells growing or turning into unintended tissue elsewhere in the body, and contamination during processing or missing tests for infections such as hepatitis and HIV.Important patient and consumer information about regenerative medicine therapies These are category-level warnings, not complication rates for every product or a formula linking risk to cell number.
Why processing changes the count
How the staff obtained and handled the cells shapes what your count actually describes:
- Same-day tissue mixtures. A count of a mixed cell population is not automatically a count of stem cells. Ask which population was identified and counted.
- Culture-expanded populations. Growing cells in culture adds processing steps. Ask what expansion and quality-control records apply to the preparation.
- Frozen and thawed products come with a storage history. The freezing method, storage period, transport, and thawing method can affect viability and function.
Get the processing steps in plain language and in writing, then read the count against those steps.
Why dose is more than one count
A dosing regimen includes the amount per administration, the route, the number of administrations, and their timing. If every administration contains the same number of cells, the course total is that number multiplied by the number of administrations. If amounts vary, add the individual amounts. Comparing totals also requires the same counting basis, such as viable cells of the same intended type.
An approved dosing example
On December 18, 2024, the FDA approved remestemcel-L-rknd (Ryoncil), an allogeneic bone-marrow-derived mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months of age and older — the first FDA-approved MSC therapy. The FDA approval notice describes 2 × 106 MSCs per kilogram of body weight per intravenous infusion, twice per week for 4 consecutive weeks: 8 infusions, at least 3 days apart. The supporting study was a multicenter, prospective, single-arm study in 54 pediatric patients after allogeneic hematopoietic stem cell transplantation.Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric A single-arm study has no concurrent comparison group; it cannot establish that a higher cell count is better than a lower one.
That regimen, population, route, and schedule belong to that product and disease. They are not a dosing guide for an unrelated joint injection, infusion program, or wellness offer.
What one regimen shows can’t tell you what a higher count, a different route, or an extra session would do. Repeat treatment needs its own evidence, so don’t assume that splitting a dose makes it safer or that extra sessions help.
Why the same count differs by condition
The same preparation can act differently across diseases, disease stages, prior treatments, and general health. Evidence tied to one diagnosis does not move automatically to joint pain, aging concerns, or an unrelated condition just because the numbers look alike.
Regulatory approval has a defined scope, including the product, indication, patient population, and conditions of use. An approved product, an experimental intervention being studied in a trial, and a service offered by a private clinic are not interchangeable categories. A clinic’s commercial availability does not establish that its intervention is approved or effective.
In Japan, the regenerative-medicine compliance framework includes distinct legal routes. PMDA describes the Act on the Safety of Regenerative Medicine as covering research and clinical practice, while the PMD Act regulates commercialization of regenerative medical products.0003 MHLW separately lists procedures for submitting treatment and research plans under the safety framework. A submitted treatment plan is not a marketing approval for a regenerative medical product and is not, by itself, proof of clinical benefit.Index
A trial registration records a planned or ongoing study; it does not establish successful completion or efficacy. Likewise, PubMed indexing helps locate a publication but does not, by itself, establish the quality of its evidence.
Same count, different offers
| What to compare | Why it changes the meaning of the count |
|---|---|
| Total versus viable cells | A total count can include nonviable cells; viability alone still does not establish function or benefit |
| Which cells were counted | Intended cells versus mixed populations give different numbers |
| Fresh versus thawed | A pre-freezing measurement may not describe the preparation after thawing |
| Per administration versus per course | 100 million once is not the same offer as 100 million twice |
| Route and schedule | Infusion and injection differ in procedure, monitoring, and evidence |
| Release and safety testing | Sterility, screening, and processing controls sit outside the count |
| Source and processing | Your own cells versus donor cells, mixed versus expanded, change the questions you ask |
A worked comparison
| Comparison item | Plan A | Plan B |
|---|---|---|
| Per visit | 100 million cells | 100 million cells |
| Number of visits | 1 | 2 |
| Course total | 100 million | 200 million |
Those visit numbers are just arithmetic, not treatment advice. Without the per-visit amount, visit count, viability, cell identity, route, and price basis, the shared 100-million headline doesn’t make the plans equal.
How to resolve a missing detail
Consider an illustrative comparison: one document says “100 million cells before freezing,” while another says “80 million viable cells after thawing.” You cannot determine the first preparation’s post-thaw viable-cell content from those statements. Ask for the relevant batch report and the measurement method and timing, rather than assuming that the larger number is better.
“Does this number refer to total or viable cells? Which cell population was measured, and at what stage? What documentation describes the preparation intended for administration?”
If those details are unavailable, record the comparison as unresolved. These examples demonstrate how to read documents; they do not describe patient outcomes or firsthand treatment experience.
What to ask instead of trusting the count
Get these details in writing before you rank any two counts:
- Does the figure mean total or viable cells, which population was counted, and when and how was viability measured?
- What records identify the cell type, tissue source, purity, and relevant biological activity?
- Is the amount per injection, site, visit, or course? What are the number and timing of administrations?
- Is the dose fixed or weight-based? What evidence supports that regimen for this condition?
- Are the cells fresh or thawed, patient-derived or donor-derived, and what processing and storage records are available?
- Which screening and release tests apply, which results are available before administration, and how are pending results handled?
- What route, volume, and rate are proposed, and what monitoring and reaction-management arrangements are in place?
- What follow-up is included, who manages complications after you return home, and what alternatives should you discuss with your clinician?
Need to clarify the documents for a proposed appointment? Ask which cell-count, processing, and cost details are available. Treatment suitability requires assessment by your clinician.
What cell count cannot promise
No single count works as the effective or safe number across products, conditions, and routes. Evidence must match the product, the people studied, the amount per administration, the schedule, the route, the definition of benefit, the follow-up period, and the harms tracked.
Marketing that ties a count straight to a result leaves too much out when it skips those details. And a transplant regimen or an unrelated study cannot serve as a benchmark for a private-clinic injection.
This guide is for orientation. It is not medical advice. A clinician who knows your diagnosis, stage, prior treatment, and general health needs to judge whether any cell-based option fits you.
Bottom line
Use cell count to describe an amount, not to rank treatment quality. Before comparing two offers, align the cell population, total-versus-viable basis, measurement timing, route, and course schedule. Then evaluate the safety documentation and evidence for the specific condition. If the offers differ on those points, their headline numbers are not a reliable basis for choosing between them.
Sources checked
The sources below were checked on 06 November 2026. FDA sources describe the United States; PMDA and MHLW sources describe Japan. The ISCT statement concerns laboratory characterization, not regulatory approval. Internal website links provide related information and service access, not independent medical evidence.
| Source | What it supports | Region and scope | Checked |
|---|---|---|---|
| [1] Dominici et al., Cytotherapy 2006 | ISCT’s three minimal laboratory criteria for human multipotent MSCs | Laboratory characterization; not evidence of clinical efficacy | 06 Nov 2026 |
| [2] FDA, regenerative medicine consumer information | Unapproved-product scope and category-level safety concerns | United States; not product-specific complication rates | 06 Nov 2026 |
| [3] FDA, remestemcel-L-rknd approval notice | Approval date, product, indication, population, dose and schedule, study design and size | United States; Ryoncil and the stated pediatric indication only | 06 Nov 2026 |
| [4] PMDA, regenerative medical products framework | Japan: distinction between the safety framework for research and clinical practice and the PMD Act route for commercialization | Japan; legal framework, not an individual clinic assessment | 06 Nov 2026 |
| [5] MHLW, regenerative medicine policy and procedures | Japan: safety-framework procedures and separate submission routes for treatment and research plans | Japan; procedural requirements, not efficacy evidence | 06 Nov 2026 |




